Prostatype Genomics AB intends to carry out a directed share issue of approximately SEK 24 million
- Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that the Company intends to carry out a directed share issue of approximately SEK 24 million to Swedish and international investors. The Company has assigned Sedermera Fondkommission to act as bookrunner in connection with the directed share issue. The capital raise is intended to finance activities carried out within the previously announced agreement with Proteomedix AG (“Proteomedix”).Cooperation with Proteomedix Proteomedix develops a next generation blood test for prostate cancer. The product complements